A 2025 medical conference for exploring treatment protocols for a new class of immune-mediated chronic illness

A Need to Understand Treatments and Determine Protocols

There continues to be a great deal of controversy regarding treatment for infectious induced immune dysregulation manifesting as PANS/PANDAS, ME/CFS, fibromyalgia, chronic pain, chronic Lyme disease, neuropsychiatric disorders and long COVID, which plagues over 20 million Americans alone.

Currently, there are still no clear protocols on how to treat these illnesses, leaving physicians frustrated and patients continuing to suffer, often seeing multiple physicians and usually without much success.

In addition to the treatments themselves continuing to be evaluated and debated within the medical community, the proper dosing, timing and usage are also collectively inconclusive. The gap in a collective answer for these treatments and their usage became evident in our 2023 annual conference. Many leading clinicians agreed that despite the research that shows these treatments to be effective, there still is not a collective understanding of them let alone how to properly utilize them to treat these specific illnesses.

Our Conference Serves to Begin Protocol Development

To address this, The Foundation for Total Recovery is developing its third international medical conference in 2025 that brings together world-leading experts to explore the use of cutting edge treatments:
  • null
    Intravenous immune globulin (IVIG) therapy
  • null
    Rituximab
  • null
    Plasmapheresis
  • null
    Experimental stem cell treatment
  • null
    Immunosuppressants
  • null
    Ketamine
  • null
    Nutraceuticals
  • null
    New biologics
  • null
    Chimeric antigen receptors (CARs)
  • null
    The role of integrative medicine approaches

    – Leucovorin

    – Mitochondrial Support

    – Oxidative Stress Support

    – Microbiome Support

Topic Areas

Our topics will discuss the intersection of chronic illnesses and neuropsychiatric conditions, diagnostics and the treatments available to help those that suffer once and for all.
  • null
    Autoimmune conditions
  • null
    Cognitive changes
  • null
    Psychiatric disorders as inflammatory disease
  • null
    PANS/PANDAS
  • null
    ME/CFS
  • null
    Fibromyalgia
  • null
    Chronic pain
  • null
    Chronic Lyme disease
  • null
    Long COVID
  • null
    Sleep disturbances and narcolepsy within this population of patients
  • null
    Utilizing AI in healthcare
  • null
    Expanding on treatment protocols using AI
  • null
    Mitochondrial Dysfunction
  • null
    Cerebral Folate Deficiency
  • null
    And more
  • null

    The Process

    This conference will serve to address these questions by the selected experts, who will review the research available for these conditions and provide their clinical responses to these therapies to determine collective protocol solutions.

  • null

    The Goal

    The goal of this conference is to establish the framework for these clinicians to ultimately make collective recommendations to medical professionals, insurance companies and stakeholder organizations on proper treatment protocols. With the results from this conference, we plan to begin the development a guideline for the medical industry to understand how to use these therapies and treat these conditions more effectively.

  • null

    Who Can Attend

Primary: Healthcare Practitioners

The educational sessions and discussions from this conference will be available in-person and virtually to healthcare providers. This conference will offer continuing medical education (CME) credit and be made available for purchase. Fields of interest include:

  • null
    Integrative medicine
  • null
    Osteopathy
  • null
    Functional medicine
  • null
    Family medicine
  • null
    Pediatric
  • null
    Neurology
  • null
    Psychiatry
  • null
    Science and research

Secondary: General Public

The conference will also be available to attend virtually or to purchase by patients, caregivers and the general public.

  • null

    When?

    This conference is currently being developed and is being planned for Spring 2025.

Sponsorship Opportunities

We are currently accepting sponsorship opportunities for the development of this conference. If you represent an organization that is interested in partnering with us, please email us at

[email protected]

The Medical Planning Board

Gary Kaplan, DO, DABFM, DABPM, FAAMA

Medical Director, Kaplan Center for Integrative Medicine; Clinical Associate Professor, Family Medicine at Georgetown University School of Medicine, Washington, D.C.
craig shimasaki

Craig Shimasaki, PhD, MBA

CEO, Moleculera Labs; Adjunct Professor, University of Oklahoma, Oklahoma City, OK

Richard E. Frye, MD, PhD

Director, Research and Neurology, Principal Investigator, Southwest Autism Research and Resource Center; President, Autism Discover and Treatment Foundation; Child Neurologist, Rossignol Medical Center, Phoenix, AZ

Isaac Melamed, MD

Owner/CEO, Veros; Member of IMMUNOe Health and Research Centers, Centennial, CO